Side-by-side · Research reference

PinealonvsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/36 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

Pinealon

Prostamax

Primary target

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

—

Origin

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

—

02Dosage Protocols

Parameter

Pinealon

Prostamax

Standard dose

5–10 mg / day for 10 daysKhavinson 2014

—

Frequency

Once daily during cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical trials + in vitroKhavinson 2014

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Duration

10-day cycles, 1–2× per year

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Reconstitution

Bacteriostatic water

—

Timing

No specific time

—

Half-life

Hours

—

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

04Side Effects & Safety

Parameter

Pinealon

Prostamax

Injection site reaction

Mild irritation

—

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

—

Published adverse events

—

None reported in available literature

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Human safety data

—

Absent — no published Phase 1/2/3 trials

Absolute Contraindications

Pinealon

·Pregnancy / breastfeeding

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

Pinealon

·Active malignancy (theoretical via gene expression modulation)

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

Pinealon

Prostamax

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Injection site

SQ — abdomen preferred.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Daily during cycle, any time.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Needle

29–31G, 4–8 mm insulin syringe.

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

06Stack Synergy

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003

Prostamax

— no documented stacks